(1-乙酰基-环戊基)-乙酸 | 859817-04-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: (1-乙酰基-环戊基)-乙酸
• 英文名称: (1-acetyl-cyclopentyl)-acetic acid
• 英文别名: 1-Acetyl-cyclopentan-essigsaeure-(1)；(1-Acetyl-cyclopentyl)-essigsaeure；2-(1-Acetylcyclopentyl)acetic acid
• CAS: 859817-04-2
• 化学式: C₉H₁₄O₃
• 分子量: 170.208
• InChiKey: FUPRUCURJPOLAW-UHFFFAOYSA-N

物化性质

• 熔点：
  83-84 °C
• 沸点：
  312.7±15.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-乙酰基-环戊基)-乙酸 在 乙醇 、 sodium 作用下， 生成 1-methyl-2-oxa-spiro[4.4]nonan-3-one
  参考文献：
  名称：

  Bardhan, Journal of the Chemical Society, 1928, p. 2616

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基碘化锌 、 alkaline earth salt of/the/ methylsulfuric acid 在 苯 作用下， 生成 (1-乙酰基-环戊基)-乙酸
  参考文献：
  名称：

  Bardhan, Journal of the Chemical Society, 1928, p. 2616

  摘要：

  DOI：

文献信息

• 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：EP2374812A2

  公开（公告）日：2011-10-12

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18, R19, n, M, , n, M, , and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  本发明提供了式 I 的 4-氨基-4-氧代丁酰基肽化合物 及其药用盐和水合物。 变量 R1-R9、R16、R18、R19、n、M、、n、M、和 Z 在本文中定义。某些式 I 化合物可用作抗病毒剂。本文公开的某些 4-氨基-4-氧代丁酰基肽化合物是病毒复制，特别是丙型肝炎病毒复制的强效和/或选择性抑制剂。本发明还提供了含有一种或多种 4-氨基-4-氧代丁酰基肽化合物和一种或多种药学上可接受的载体的药物组合物。这种药物组合物可以含有4-氨基-4-氧代丁酰基肽化合物作为唯一的活性剂，也可以含有含4-氨基-4-氧代丁酰基肽化合物和一种或多种其他药物活性剂的组合。本发明还提供了治疗哺乳动物病毒感染（包括丙型肝炎感染）的方法。
• NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20140113890A1

  公开（公告）日：2014-04-24

  The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：ACHILLION PHARMACEUTICALS, INC.

  公开号：US20140328796A1

  公开（公告）日：2014-11-06

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
• US8785378B2
  申请人：——

  公开号：US8785378B2

  公开（公告）日：2014-07-22
• US9133115B2
  申请人：——

  公开号：US9133115B2

  公开（公告）日：2015-09-15